Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Birzeit Pharmaceutical Co shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Birzeit Pharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2026 was 84.02.
Birzeit Pharmaceutical Co's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.02.
As of today, Birzeit Pharmaceutical Co's Altman Z-Score is 4.15.
Birzeit Pharmaceutical Co (XPAE:BPC) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Birzeit Pharmaceutical Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Birzeit Pharmaceutical Co Financial Strength Related Terms
XPAE:BPC vs ZTS, UTHR, VTRS: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Financial Strength vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Financial Strength distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Birzeit Pharmaceutical Co had no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Birzeit Pharmaceutical Co has enough cash to cover all of its debt. Its financial situation is stable.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Birzeit Pharmaceutical Co has a Z-score of 4.15, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 4.15 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Financial Strength of 10 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Birzeit Pharmaceutical Co's Financial Strength has ranged from 4.00 to 10.00.
Is Birzeit Pharmaceutical Co's Financial Strength too high?
Birzeit Pharmaceutical Co's current Financial Strength of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Financial Strength compare to ZTS and UTHR?
Birzeit Pharmaceutical Co's Financial Strength of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Birzeit Pharmaceutical Co's own Financial Strength has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Birzeit Pharmaceutical Co and its competitors. Birzeit Pharmaceutical Co's current Financial Strength is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Fairly Valued. The stock's GF Value™ is $4.34, compared to a current price of $3.95 — trading 9% below its estimated fair value. The current Financial Strength is 10, which is 11% above median its 10-year median of 9.00. Birzeit Pharmaceutical Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Financial Strength is 10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.95 is trading 9% below its estimated GF Value™ of $4.34.
GuruFocus considers Birzeit Pharmaceutical Co to be Fairly Valued.
Key valuation signals for XPAE:BPC:
Financial Strength: 10 (11% above median its 10-year median of 9.00)
GF Value™: $4.34 vs. price of $3.95 (9% below fair value)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
86GF Score
Get the complete analysis for XPAE:BPC
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
